Home › Trial NCT03505372
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
- Trial IDNCT03505372
- StatusTerminated
- PhaseN/A
- Study typeInterventional
- SponsorDana-Farber Cancer Institute
- Enrollment5
- Start date2018-05-10
- ConditionsAtypical Ductal Hyperplasia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.